Volatility Shares Trust 2x Ether ETF

GraniteShares 1.5x Long Coinbase Daily ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily TSLA Bull 1.5X Shares

Altimmune Inc. Common Stock

iShares Ethereum Trust ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

Mast Therapeutics, Inc.

Direxion Daily Gold Miners Bear 3X ETF

ProShares UltraShort Silver

T-REX 2X Inverse Tesla Daily Target ETF

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily 20+ Yr Trsy Bear 3X ETF

VS TR 2x Long VIX Futures ETF

Direxion Daily Gold Miners Bull 3X ETF

ProShares Ultra Silver

Tuttle Capital Short Innovation ETF

ProShares Ultra VIX Short-Term Futures

VanEck Vectors Junior Gold Miners ETF

Direxion Daily Small Cap Bear 3X ETF

Incannex Healthcare Limited American Depositary Shares

Treasure Global Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

Gryphon Digital Mining Inc Common Stock

Amicus Therapeutics Inc. Common Stock

Bioventus Inc. Class A Common Stock

Annexon Inc. Common Stock

Plug Power Inc. Common Stock

Nuvve Holding Corp. Common Stock

Vistra Corp. Common Stock

Click Holdings Limited Ordinary Share

Aytu BioPharma Inc.  Common Stock

Arcturus Therapeutics Holdings Inc. Common Stock

Applied Materials Inc. Common Stock

LOBO EV TECHNOLOGIES LTD. Ordinary shares

Theriva Biologics Inc. Common Stock

ScanTech AI Systems Inc. Common stock

Take-Two Interactive Software Inc. Common Stock

Premier Inc. Class A Common Stock

Kindly MD Inc. Common Stock

Click here to get full coverage on GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire

GRI Bio Reports First Quarter 2025 Financial Results and  GlobeNewswire

GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire

Click here to get full coverage on CSR Reports and Reporting Standards - TotalEnergies.com

CSR Reports and Reporting Standards  TotalEnergies.com

CSR Reports and Reporting Standards - TotalEnergies.com

Click here to get full coverage on GRI Bio reports positive early trial data for IPF treatment - Investing.com

GRI Bio reports positive early trial data for IPF treatment  Investing.com

GRI Bio reports positive early trial data for IPF treatment - Investing.com

Click here to get full coverage on Sustainability Reporting - Realty Income

Sustainability Reporting  Realty Income

Sustainability Reporting - Realty Income

Click here to get full coverage on GRI Bio, Inc. SEC 10-Q Report - TradingView

GRI Bio, Inc. SEC 10-Q Report  TradingView

GRI Bio, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)  Yahoo Finance

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance

Click here to get full coverage on MSC Announcement: GRI - General rate increase and additional scopes - American Journal of Transportation

MSC Announcement: GRI - General rate increase and additional scopes  American Journal of Transportation

MSC Announcement: GRI - General rate increase and additional scopes - American Journal of Transportation

Click here to get full coverage on GRI Bio Announces Pricing of $5.0 Million Public Offering - GlobeNewswire

GRI Bio Announces Pricing of $5.0 Million Public Offering  GlobeNewswire

GRI Bio Announces Pricing of $5.0 Million Public Offering - GlobeNewswire

Click here to get full coverage on GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Stock Titan

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)  Stock Titan

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Stock Titan

Click here to get full coverage on GRI Bio Announces Reverse Stock Split - GlobeNewswire

GRI Bio Announces Reverse Stock Split  GlobeNewswire

GRI Bio Announces Reverse Stock Split - GlobeNewswire

Click here to get full coverage on GRI Bio Announces Closing of $5.0 Million Public Offering - GlobeNewswire

GRI Bio Announces Closing of $5.0 Million Public Offering  GlobeNewswire

GRI Bio Announces Closing of $5.0 Million Public Offering - GlobeNewswire

Click here to get full coverage on GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire

GRI Bio Announces Abstract Selected for Poster Discussion  GlobeNewswire

GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire

Click here to get full coverage on GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)  GlobeNewswire

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire

Click here to get full coverage on GRI-GM42 specification for high-performance HDPE geomembranes - Geosynthetics Magazine

GRI-GM42 specification for high-performance HDPE geomembranes  Geosynthetics Magazine

GRI-GM42 specification for high-performance HDPE geomembranes - Geosynthetics Magazine

Click here to get full coverage on GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Stock Titan

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)  Stock Titan

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Stock Titan

Click here to get full coverage on GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan  GlobeNewswire

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire

Click here to get full coverage on GRI Bio Secures $5M Funding Deal: Warrants Could Add $13.3M More - Stock Titan

GRI Bio Secures $5M Funding Deal: Warrants Could Add $13.3M More  Stock Titan

GRI Bio Secures $5M Funding Deal: Warrants Could Add $13.3M More - Stock Titan

Click here to get full coverage on GRI Appoints Robin Hodess as New CEO - ESG Today

GRI Appoints Robin Hodess as New CEO  ESG Today

GRI Appoints Robin Hodess as New CEO - ESG Today

Click here to get full coverage on PEZA, GRI launch sustainability reporting guide for exporters - PortCalls Asia

PEZA, GRI launch sustainability reporting guide for exporters  PortCalls Asia

PEZA, GRI launch sustainability reporting guide for exporters - PortCalls Asia

Click here to get full coverage on GRI, CDP to Strengthen Alignment of Sustainability Reporting Frameworks - ESG Today

GRI, CDP to Strengthen Alignment of Sustainability Reporting Frameworks  ESG Today

GRI, CDP to Strengthen Alignment of Sustainability Reporting Frameworks - ESG Today

Click here to get full coverage on Global Reporting Initiative (GRI) Appoints Robin Hodess as New CEO - ESG News

Global Reporting Initiative (GRI) Appoints Robin Hodess as New CEO  ESG News

Global Reporting Initiative (GRI) Appoints Robin Hodess as New CEO - ESG News

Click here to get full coverage on Clinical Trial Breakthrough: GRI-0621 Clears Key Safety Milestone for IPF Treatment - Stock Titan

Clinical Trial Breakthrough: GRI-0621 Clears Key Safety Milestone for IPF Treatment  Stock Titan

Clinical Trial Breakthrough: GRI-0621 Clears Key Safety Milestone for IPF Treatment - Stock Titan

Click here to get full coverage on Global Reporting Initiative: Literature review and research directions - ScienceDirect.com

Global Reporting Initiative: Literature review and research directions  ScienceDirect.com

Global Reporting Initiative: Literature review and research directions - ScienceDirect.com

Click here to get full coverage on Global Patent Victory: GRI Bio's Breakthrough NKT Cell Treatment for Autoimmune Disease Gets Dual Approval - Stock Titan

Global Patent Victory: GRI Bio's Breakthrough NKT Cell Treatment for Autoimmune Disease Gets Dual Approval  Stock Titan

Global Patent Victory: GRI Bio's Breakthrough NKT Cell Treatment for Autoimmune Disease Gets Dual Approval - Stock Titan

Click here to get full coverage on GRI Appoints Tharindu Atapattu as CEO - Modern Tire Dealer

GRI Appoints Tharindu Atapattu as CEO  Modern Tire Dealer

GRI Appoints Tharindu Atapattu as CEO - Modern Tire Dealer

Click here to get full coverage on GRI Wins Award at ProMat Show - Modern Tire Dealer

GRI Wins Award at ProMat Show  Modern Tire Dealer

GRI Wins Award at ProMat Show - Modern Tire Dealer

Click here to get full coverage on GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - GlobeNewswire

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds  GlobeNewswire

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - GlobeNewswire

Click here to get full coverage on Can GRI Bio's 17:1 Reverse Split Save Its Nasdaq Listing? Key Details Revealed - Stock Titan

Can GRI Bio's 17:1 Reverse Split Save Its Nasdaq Listing? Key Details Revealed  Stock Titan

Can GRI Bio's 17:1 Reverse Split Save Its Nasdaq Listing? Key Details Revealed - Stock Titan

Click here to get full coverage on GRI Bio reports positive interim biomarker data in IPF study - Investing.com

GRI Bio reports positive interim biomarker data in IPF study  Investing.com

GRI Bio reports positive interim biomarker data in IPF study - Investing.com

Click here to get full coverage on GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - Nasdaq

GRI Stock Down on Public Offering Despite Encouraging IPF Study Data  Nasdaq

GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - Nasdaq

Click here to get full coverage on GRI Bio Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire

GRI Bio Participates in a Virtual Investor CEO Connect Segment  GlobeNewswire

GRI Bio Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire

Click here to get full coverage on reporting disclosure standards in Public Institutions and State-Owned Companies of - ResearchGate

reporting disclosure standards in Public Institutions and State-Owned Companies of  ResearchGate

reporting disclosure standards in Public Institutions and State-Owned Companies of - ResearchGate

Click here to get full coverage on GRI Bio Announces Exercise of Warrants - GlobeNewswire

GRI Bio Announces Exercise of Warrants  GlobeNewswire

GRI Bio Announces Exercise of Warrants - GlobeNewswire

Click here to get full coverage on MSC Announcement: See GRI and Demurrage increases - American Journal of Transportation

MSC Announcement: See GRI and Demurrage increases  American Journal of Transportation

MSC Announcement: See GRI and Demurrage increases - American Journal of Transportation

Click here to get full coverage on GRI Bio's Breakthrough IPF Drug Shows Promise, Key Data Coming Next Quarter - Stock Titan

GRI Bio's Breakthrough IPF Drug Shows Promise, Key Data Coming Next Quarter  Stock Titan

GRI Bio's Breakthrough IPF Drug Shows Promise, Key Data Coming Next Quarter - Stock Titan

Click here to get full coverage on GHG Protocol Adds CDP, EFRAG, GRI, ISSB, and SBTi to Strengthen Climate Reporting Alignment - ESG News

GHG Protocol Adds CDP, EFRAG, GRI, ISSB, and SBTi to Strengthen Climate Reporting Alignment  ESG News

GHG Protocol Adds CDP, EFRAG, GRI, ISSB, and SBTi to Strengthen Climate Reporting Alignment - ESG News

Click here to get full coverage on Shipping from the East Coast of South America*? A GRI is coming up - Hapag-Lloyd

Shipping from the East Coast of South America*? A GRI is coming up  Hapag-Lloyd

Shipping from the East Coast of South America*? A GRI is coming up - Hapag-Lloyd

Click here to get full coverage on GRI Bio Secures Future on Nasdaq: Key Compliance Achievement Signals Stability - Stock Titan

GRI Bio Secures Future on Nasdaq: Key Compliance Achievement Signals Stability  Stock Titan

GRI Bio Secures Future on Nasdaq: Key Compliance Achievement Signals Stability - Stock Titan

Click here to get full coverage on GRI Bio's IPF Treatment Shows Promise: Key Clinical Data Coming in 2025 - Stock Titan

GRI Bio's IPF Treatment Shows Promise: Key Clinical Data Coming in 2025  Stock Titan

GRI Bio's IPF Treatment Shows Promise: Key Clinical Data Coming in 2025 - Stock Titan

Click here to get full coverage on Global Reporting Initiative's New Banking Sector Standard: Highlights and Latest Developments - Sustainalytics

Global Reporting Initiative's New Banking Sector Standard: Highlights and Latest Developments  Sustainalytics

Global Reporting Initiative's New Banking Sector Standard: Highlights and Latest Developments - Sustainalytics

Click here to get full coverage on India-US carriers attempt strategic capacity cuts to prop up March GRI plans - Journal of Commerce

India-US carriers attempt strategic capacity cuts to prop up March GRI plans  Journal of Commerce

India-US carriers attempt strategic capacity cuts to prop up March GRI plans - Journal of Commerce

Click here to get full coverage on Government Restrictions on Religion Stayed at Peak Levels Globally in 2022 - Pew Research Center

Government Restrictions on Religion Stayed at Peak Levels Globally in 2022  Pew Research Center

Government Restrictions on Religion Stayed at Peak Levels Globally in 2022 - Pew Research Center

Click here to get full coverage on GRI Launches New Service to Help Reporting Companies Comply with CSRD Sustainability Reporting Standards - ESG Today

GRI Launches New Service to Help Reporting Companies Comply with CSRD Sustainability Reporting Standards  ESG Today

GRI Launches New Service to Help Reporting Companies Comply with CSRD Sustainability Reporting Standards - ESG Today

Click here to get full coverage on 51 courses to sort through the details of sustainability disclosure standards - Trellis Group

51 courses to sort through the details of sustainability disclosure standards  Trellis Group

51 courses to sort through the details of sustainability disclosure standards - Trellis Group

Click here to get full coverage on GRI Announces New Chief Executive Officer - aftermarketNews

GRI Announces New Chief Executive Officer  aftermarketNews

GRI Announces New Chief Executive Officer - aftermarketNews

Click here to get full coverage on 11 courses to help you determine which sustainability reporting and disclosure tools to use - Trellis Group

11 courses to help you determine which sustainability reporting and disclosure tools to use  Trellis Group

11 courses to help you determine which sustainability reporting and disclosure tools to use - Trellis Group

Click here to get full coverage on GHG Protocol Adds CDP, EFRAG, GRI, ISSB, and SBTi to Strengthen Climate Reporting Alignment - Seneca ESG

GHG Protocol Adds CDP, EFRAG, GRI, ISSB, and SBTi to Strengthen Climate Reporting Alignment  Seneca ESG

GHG Protocol Adds CDP, EFRAG, GRI, ISSB, and SBTi to Strengthen Climate Reporting Alignment - Seneca ESG

Click here to get full coverage on Sustainability reports, ratings & figures - Siemens

Sustainability reports, ratings & figures  Siemens

Sustainability reports, ratings & figures - Siemens

Click here to get full coverage on GRI Bio Announces $5 Million Public Offering Amid Market Decline - Nasdaq

GRI Bio Announces $5 Million Public Offering Amid Market Decline  Nasdaq

GRI Bio Announces $5 Million Public Offering Amid Market Decline - Nasdaq

Click here to get full coverage on GRI Bio announces $5 million public offering - Investing.com

GRI Bio announces $5 million public offering  Investing.com

GRI Bio announces $5 million public offering - Investing.com

Click here to get full coverage on MSC Announcement: GRI - General Rate Increase Feb 2025 - American Journal of Transportation

MSC Announcement: GRI - General Rate Increase Feb 2025  American Journal of Transportation

MSC Announcement: GRI - General Rate Increase Feb 2025 - American Journal of Transportation

Click here to get full coverage on GRI Bio appoints Withum as new accounting firm - Investing.com

GRI Bio appoints Withum as new accounting firm  Investing.com

GRI Bio appoints Withum as new accounting firm - Investing.com

Click here to get full coverage on W&M’s Global Research Institute announces Accelerate Initiative to raise $10M - W&M News

W&M’s Global Research Institute announces Accelerate Initiative to raise $10M  W&M News

W&M’s Global Research Institute announces Accelerate Initiative to raise $10M - W&M News

Click here to get full coverage on GRI Bio approves reverse stock split, stockholders vote in favor - Investing.com

GRI Bio approves reverse stock split, stockholders vote in favor  Investing.com

GRI Bio Inc. (GRI)

Price Chart

Key Statistics

Technicals

About GRI

Latest News

GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire

CSR Reports and Reporting Standards - TotalEnergies.com

GRI Bio reports positive early trial data for IPF treatment - Investing.com

Advanced Charts

Top Gainers

Top Losers